University of California Los Angeles Department of Medicine
Welcome,         Profile    Billing    Logout  
 11 Trials 
18 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lenz, Heinz-josef
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Active, not recruiting
2
234
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care
Agenus Inc.
Metastatic Colorectal Cancer
02/25
07/25
NCT05733611: RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Active, not recruiting
2
4
NA
RP2, RP3, atezolizumab, bevacizumab
Replimune Inc., Roche Pharma AG
Refractory Metastatic Colorectal Cancer, pMMR, MSS
01/27
03/27
NCT06187402: A Study of LM-24C5 For Advanced Solid Tumors

Recruiting
1/2
49
US
LM-24C5
LaNova Medicines Limited
Advanced Solid Tumor
06/25
03/26
ELIMYN18.2, NCT04404595: Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

Active, not recruiting
1/2
110
Canada, US
CT041
CARsgen Therapeutics Co., Ltd.
Gastric Cancer, Pancreatic Cancer
06/25
09/35
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting
1/2
374
Europe, Canada, Japan, US, RoW
Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil
Takeda, Takeda Development Center Americas, Inc. (TDC Americas)
Solid Neoplasms
01/26
01/26
AFNT211-22-101, NCT06105021: Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects with Advanced or Metastatic Solid Tumor

Recruiting
1/2
100
US
AFNT-211
Affini-T Therapeutics, Inc.
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
12/25
12/29
NCT04505839: First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors

Completed
1
32
US
STP1002, Basroparib
ST Pharm Co., Ltd., KCRN Research, LLC
Advanced Solid Tumor
03/23
03/23
STAR, NCT04053283: First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector

Active, not recruiting
1
186
US
NG-641
Akamis Bio
Metastatic Cancer, Epithelial Tumor
08/24
12/24
ACTM-838-01, NCT06336148: A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Recruiting
1
35
US, RoW
ACTM-838
Actym Therapeutics, Inc.
Solid Tumor
01/26
07/26
KISIMA-01, NCT04046445: Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

Active, not recruiting
1
96
Europe, US
ATP128, BI 754091, Ezabenlimab, VSV-GP128
Amal Therapeutics, Boehringer Ingelheim
Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer, Metastatic Colorectal Cancer, Liver Metastasis Colon Cancer
05/25
08/25
KISIMA-02, NCT05846516: A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC

Recruiting
1
85
Europe, US
VSV-GP154, ATP150, ATP152, Ezabenlimab
Amal Therapeutics, Boehringer Ingelheim
Pancreatic Ductal Adenocarcinoma
12/26
03/27
Hannigan, Chris
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma

Recruiting
2
123
US
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
CARGO Therapeutics
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
09/25
12/26
AFNT211-22-101, NCT06105021: Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects with Advanced or Metastatic Solid Tumor

Recruiting
1/2
100
US
AFNT-211
Affini-T Therapeutics, Inc.
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
12/25
12/29
NCT06218914: A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation

Recruiting
1
24
US
NT-112: Autologous, engineered T Cells targeting KRAS G12D
AstraZeneca
Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D
08/27
08/40
LYL845-101, NCT05573035: A Study to Investigate LYL845 in Adults With Solid Tumors

Active, not recruiting
1
108
US
LYL845
Lyell Immunopharma, Inc.
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
08/25
09/27
NT-175-201, NCT05877599: A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Recruiting
1
162
US
Autologous, engineered T Cells targeting TP53 R175H
AstraZeneca
Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer
09/28
08/39

Download Options